• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Shannon Ellis

Articles by Shannon Ellis

Top pharma, banking execs flocking to pre-revenue startups in China

July 18, 2018
By Shannon Ellis
SHANGHAI – China's biotechs are benefiting from an unprecedented blood transfusion. Experienced executives from global pharma companies, and increasingly even big banks, are taking the leap to startups, leaving stable jobs behind. The incentive? Pay packages with stock options that can be worth tens of millions of dollars.
Read More

Zai moves Tesaro's PARP inhibitor into China phase III in first-line ovarian cancer maintenance

July 11, 2018
By Shannon Ellis
SHANGHAI – Zai Labs Ltd. has kicked off a phase III China study of ZL-2306 (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor that prolongs the life of women with ovarian cancer.
Read More

Zai moves Tesaro's PARP inhibitor into China phase III in first-line ovarian cancer maintenance

July 6, 2018
By Shannon Ellis
SHANGHAI – Zai Labs Ltd. has kicked off a phase III China study of ZL-2306 (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor that prolongs the life of women with ovarian cancer.
Read More

As first PD-1 inhibitor, Opdivo looks set to do well in China, for a while

June 27, 2018
By Shannon Ellis
SHANGHAI – Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has become the first PD-1 inhibitor to be approved for patients in China, in a classic example that China' drug lag is real. Chinese lung patients will have access to the cutting edge immuno-oncology (I-O) therapy four years after it was first approved in the U.S. and after it has been approved in 60 countries.
Read More

Alpha Biopharma raises $37M for brain-penetrant EGFR inhibitor program

June 26, 2018
By Shannon Ellis

SHANGHAI – Alpha Biopharma Inc., of Shanghai, closed the first tranche of its $65 million series A fund, having received $37 million from Qiming Venture Partners, TF Fund and Lyzz Healthcare Venture Fund. According to Alphabio's chief operating officer, James Liu, the remaining $28 million is expected to close in the next few months.


Read More

As first PD-1 inhibitor, Opdivo looks set to do well in China, for a while

June 25, 2018
By Shannon Ellis
SHANGHAI – Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has become the first PD-1 inhibitor to be approved for patients in China, in a classic example that China' drug lag is real. Chinese lung patients will have access to the cutting edge immuno-oncology (I-O) therapy four years after it was first approved in the U.S. and after it has been approved in 60 countries.
Read More

Alpha Biopharma raises $37M for brain-penetrant EGFR inhibitor program

June 22, 2018
By Shannon Ellis
SHANGHAI – Alpha Biopharma Inc., of Shanghai, closed the first tranche of its $65 million series A fund, having received $37 million from Qiming Venture Partners, TF Fund and Lyzz Healthcare Venture Fund. According to Alphabio's chief operating officer, James Liu, the remaining $28 million is expected to close in the next few months.
Read More

Hitgen nabs ¥250M series B, inks deal with Forma Therapeutics

June 13, 2018
By Shannon Ellis
SHANGHAI – Chengdu-based Hitgen Ltd. raised ¥250 million (US$39 million) in series B financing and inked a multi-year collaboration with Forma Therapeutics Inc, of Watertown, Mass. With a major DNA-encoded library (DEL) of small molecules, Hitgen has not found its relatively out-of-the-way location in southwestern China has held it back.
Read More

Hitgen nabs ¥250M series B, inks deal with Forma Therapeutics

June 11, 2018
By Shannon Ellis
SHANGHAI – Chengdu-based Hitgen Ltd. raised ¥250 million (US$39 million) in series B financing and inked a multi-year collaboration with Forma Therapeutics Inc, of Watertown, Mass. With a major DNA-encoded library (DEL) of small molecules, Hitgen has not found its relatively out-of-the-way location in southwestern China has held it back.
Read More

CNDA Town Hall: New drug commissioner Hong promises continued innovation support

June 6, 2018
By Shannon Ellis
BEIJING – Freshly installed Commissioner Jiao Hong of the China National Drug Administration, formerly the CFDA, voiced the agency's plans to streamline review and approval of new drugs, encourage innovation, improve capacity to take a science-based approach, deepen industry's quality control efforts and step up monitoring of adverse events.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 8, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe